Journal
CELL HOST & MICROBE
Volume 24, Issue 1, Pages 12-17Publisher
CELL PRESS
DOI: 10.1016/j.chom.2018.05.021
Keywords
-
Categories
Funding
- University of Texas Medical Branch (UTMB) startup award
- University of Texas STARs Award
- UTMB Technology Commercialization Program Award
- CDC grant for the Western Gulf Center of Excellence for Vector-Borne Diseases
- Pan American Health Organization grant [SCON2016-01353]
- Kleberg Foundation Award
- UTMB CTSA [UL1TR-001439]
- NIH grant [AI127744]
Ask authors/readers for more resources
The explosive emergence of Zika virus has inspired a global effort to develop vaccines. Zika virus, which is a flavivirus primarily transmitted by mosquitoes, can cause devastating congenital syndrome in fetuses of pregnant women, including microcephaly, craniofacial disproportion, spasticity, ocular abnormalities, and miscarriage. In adults, Zika infection has been linked to the autoimmune disorder Guillain-Barre syndrome. Thus, despite the current waning in newly reported Zika infections, an efficacious vaccine is urgently needed to help limit the emergence of another detrimental epidemic. Here we summarize the current status of the Zika vaccine pipeline and highlight the challenges for clinical efficacy trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available